| NCT05914194 | A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1 | NOT_YET_RECRUITING | PHASE3 | 2024-07-15 | 2025-07-30 | 2025-07-30 |
| NCT05055024 | An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy | COMPLETED | PHASE2 | 2021-10-26 | 2023-01-19 | 2023-01-19 |
| NCT04923594 | Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy | COMPLETED | PHASE2 | 2021-09-13 | 2022-06-30 | 2022-06-30 |
| NCT02808104 | Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | PHASE2 | 2016-08 | 2017-03-28 | 2017-03-28 |